

## ERRATA

### **Translational Readthrough of Nonsense Mutant TP53, RB1 and PTEN Tumor Suppressor Genes as a Strategy for Novel Cancer Therapy**

Mireia Palomar Siles

Doctoral thesis

ISBN 978-91-8016-926-4

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, 2023

#### **1. Correction of clinical trial status and identifier number.**

Location: page 13.

Error: “In addition, it is the most advanced Mdm2 inhibitor as phase III clinical **trials are on-going** in relapsed or refractory AML patients with this compound in combination with cytarabine (clinical trial identifier: **NCT01773408**)”.

Correction: “In addition, it is the most advanced Mdm2 inhibitor as **a phase III clinical trial was performed** in relapsed or refractory AML patients with this compound in combination with cytarabine (clinical trial identifier: **NCT02545283**)”.